Cargando…

Blood–Brain Barrier Dysfunction and Aβ42/40 Ratio Dose-Dependent Modulation with the ApoE Genotype within the ATN Framework

The definition of Alzheimer’s disease (AD) now considers the presence of the markers of amyloid (A), tau deposition (T), and neurodegeneration (N) essential for diagnosis. AD patients have been reported to have increased blood–brain barrier (BBB) dysfunction, but that has not been tested within the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Toniolo, Sofia, Di Lorenzo, Francesco, Bernardini, Sergio, Mercuri, Nicola Biagio, Sancesario, Giulia Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10418506/ https://www.ncbi.nlm.nih.gov/pubmed/37569528 http://dx.doi.org/10.3390/ijms241512151

Ejemplares similares

Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimer’s disease
por: Duong, Michael Tran, et al.
Publicado: (2022)

Aggregation States of Aβ(1–40), Aβ(1–42) and Aβp(3–42) Amyloid Beta Peptides: A SANS Study
por: Festa, Giulia, et al.
Publicado: (2019)

How Comorbidity Reflects on Cerebrospinal Fluid Biomarkers of Neurodegeneration in Aging
por: Zenuni, Henri, et al.
Publicado: (2021)

A novel study on amyloid β peptide 40, 42 and 40/42 ratio in Saudi autistics
por: Al- Ayadhi, Laila Y, et al.
Publicado: (2012)

CSF Potential Biomarkers Aβ42 and Tau: associations of Apo E Genotype
por: Kandimalla, Ramesh, et al.
Publicado: (2010)

Longitudinal change in ATN biomarkers in cognitively normal individuals
por: Ebenau, Jarith L., et al.
Publicado: (2022)

Exploring the ATN classification system using brain morphology
por: Heinzinger, Nils, et al.
Publicado: (2023)

Different associations between amyloid-βeta 42, amyloid-βeta 40, and amyloid-βeta 42/40 with soluble phosphorylated-tau and disease burden in Alzheimer’s disease: a cerebrospinal fluid and fluorodeoxyglucose-positron emission tomography study
por: Motta, Caterina, et al.
Publicado: (2023)

Annual stability of the plasma Aß40/42 ratio and associated factors
por: Nakamura, Takumi, et al.
Publicado: (2023)

Cathepsin D regulates cerebral Aβ42/40 ratios via differential degradation of Aβ42 and Aβ40
por: Suire, Caitlin N., et al.
Publicado: (2020)

The association of serum uric acid with cognitive impairment and ATN biomarkers
por: Huang, Shan, et al.
Publicado: (2022)

Surgical Outcomes of Myopic Foveoschisis According to the ATN Classification System
por: Fang, Dong, et al.
Publicado: (2022)

ATN profile classification across two independent prospective cohorts
por: Peretti, Débora E., et al.
Publicado: (2023)

CSF Aβ42 and Aβ42/Aβ40 Ratio in Alzheimer’s Disease and Frontotemporal Dementias
por: Constantinides, Vasilios C., et al.
Publicado: (2023)

The effects of an intronic polymorphism in TOMM40 and APOE genotypes in sporadic inclusion body myositis
por: Gang, Qiang, et al.
Publicado: (2015)

Tau and Amyloid-β Peptides in Serum of Patients With Parkinson's Disease: Correlations With CSF Levels and Clinical Parameters
por: Schirinzi, Tommaso, et al.
Publicado: (2022)

VALIDATION OF THE RECENTLY DEVELOPED ATN CLASSIFICATION AND GRADING SYSTEM FOR MYOPIC MACULOPATHY
por: Ruiz-Medrano, Jorge, et al.
Publicado: (2020)

Longitudinal trajectories of Alzheimer’s ATN biomarkers in elderly persons without dementia
por: Tan, Meng-Shan, et al.
Publicado: (2020)

ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project
por: Ebenau, Jarith L., et al.
Publicado: (2020)

P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status
por: Campbell, Michelle R., et al.
Publicado: (2021)

Prognostic value of imaging-based ATN profiles in a memory clinic cohort
por: Peretti, Débora E., et al.
Publicado: (2023)

Prognostic Role of CSF β-amyloid 1–42/1–40 Ratio in Patients Affected by Amyotrophic Lateral Sclerosis
por: Colletti, Tiziana, et al.
Publicado: (2021)

Allosteric Modulation of PS1/γ-Secretase Conformation Correlates with Amyloid β(42/40) Ratio
por: Uemura, Kengo, et al.
Publicado: (2009)

Frontotemporal dementia is the leading cause of “true” A−/T+ profiles defined with Aβ(42/40) ratio
por: Pouclet-Courtemanche, Hélène, et al.
Publicado: (2019)

Prediction of Alzheimer’s disease biomarker status defined by the ‘ATN framework’ among cognitively healthy individuals: results from the EPAD longitudinal cohort study
por: Calvin, Catherine M., et al.
Publicado: (2020)

Sleep Dysregulation Is Associated with (18)F-FDG PET and Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease
por: Fernandes, Mariana, et al.
Publicado: (2023)

APOE genotype and Alzheimer’s immunotherapy
por: Pankiewicz, Joanna E., et al.
Publicado: (2017)

When Cognitive Decline and Depression Coexist in the Elderly: CSF Biomarkers Analysis Can Differentiate Alzheimer's Disease from Late-Life Depression
por: Liguori, Claudio, et al.
Publicado: (2018)

Evaluation of the ATN model in a longitudinal memory clinic sample with different underlying disorders
por: Eckerström, C., et al.
Publicado: (2021)

Association between ATN profiles and mortality in a clinical cohort of patients with cognitive disorders
por: Régy, Mélina, et al.
Publicado: (2023)

Head-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaints
por: Lu, Jiaying, et al.
Publicado: (2023)

YOLOv5-Atn: An Algorithm for Residual Film Detection in Farmland Combined with an Attention Mechanism
por: Lin, Ying, et al.
Publicado: (2023)

CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease
por: Janelidze, Shorena, et al.
Publicado: (2016)

A Clinical and Biochemical Analysis in the Differential Diagnosis of Idiopathic Normal Pressure Hydrocephalus
por: Schirinzi, Tommaso, et al.
Publicado: (2015)

TOMM40 ‘523 Genotype Distinguishes Patterns of Cognitive Improvement for Executive Function in APOE ɛ3 Homozygotes
por: Watts, Amber, et al.
Publicado: (2023)

Aspects Operationnels 40 41 et 42
por: Boutheon, M
Publicado: (1978)

Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study
por: Dumurgier, Julien, et al.
Publicado: (2015)

Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals
por: Fandos, Noelia, et al.
Publicado: (2017)

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
por: Hansson, Oskar, et al.
Publicado: (2019)

Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype
por: Janelidze, Shorena, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2or79ebafjbd553hil0n32h3ev